AstraZeneca stock price steadies ahead of earnings week as TrumpRx adds drug-pricing noise
AstraZeneca shares closed up 0.9% in London at £141.04 and rose 3.2% in New York to $193.23 on Friday. The company will report full-year and Q4 results Tuesday, with investors focused on 2026 guidance. U.S. drug pricing pressure intensified after the TrumpRx rollout. AstraZeneca recently began trading ordinary shares on the NYSE, expanding its market presence.